8-K current report · filed Oct 30, 2026

AbbVie Inc (ABBV) 8-K Current Report: October 30, 2026

Item 2.02Item EX-99.1ABBV overview

Short answer

AbbVie Inc (ABBV) filed an 8-K current report with the SEC on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). AbbVie’s third-quarter 2026 financial results cover the period ended September 30, 2026.

AbbVie Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • AbbVie’s third-quarter 2026 financial results cover the period ended September 30, 2026
  • Detailed revenue, earnings, guidance and product performance are contained in Exhibit 99.1, the accompanying earnings release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $17.404B, up 10.3%, with immunology up 16.3% and neuroscience up 19.4%
  • Skyrizi revenue $5.776B and Rinvoq $2.706B, both growing over 22%, offsetting Humira’s 31.2% decline
  • GAAP EPS $2.37 versus $0.10, while adjusted EPS reached $3.82, including a $0.11 acquired IPR&D impact
  • 2026 adjusted EPS guidance raised to $13.95-$13.99 from $13.76-$13.96, despite $0.69 year-to-date acquisition-related impact
  • Apogee acquisition strengthens immunology pipeline, while 2027 dividend increases 5.2% to $1.82 quarterly beginning February 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other AbbVie Inc 8-K filings

Get the next ABBV 8-K as it lands

Follow ABBV for push alerts, or ask the research agent what this filing means.